Stockreport

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient popu [Read more]